Advertisement
Research Article| Volume 4, ISSUE 4, P803-815, December 1984

The Carcinoid Syndrome: Neuroendocrine and Chemical Considerations

DOI:https://doi.org/10.1016/S0272-2712(18)30903-X
The Carcinoid Syndrome: Neuroendocrine and Chemical Considerations
Previous ArticleProstaglandins In Human Disease
Next ArticleReceptor Measurements
      This paper is only available as a PDF. To read, Please Download here.
      The carcinoid syndrome is characterized by a complex of neuroendocrine and chemical abnormalities whose cause is not known. Carcinoids vary in their tendency to produce the carcinoid syndrome, although ileal tumors and those that have metastasized are more frequently associated with manifestations of the syndrome. The unifying concept of a neural crest origin for these and related neoplasms provides a basis for understanding the hormonal and chemical features of this disease. The extent of the various hormonal changes is only now becoming apparent and will undoubtedly expand as investigation continues in this area.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Abrams J.S.
        Multiple malignant carcinoids of the stomach.
        Arch. Surg. 1980; 115: 1219-1221
        • Adamson A.R.
        • Grahame-Smith D.G.
        • Bogomoletz W.
        • et al.
        Malignant argentaffinoma with carcinoid syndrome and hypoglycaemia.
        Br. Med. J. 1971; 3: 93-94
        • Aunis D.
        • Miras-Portugal M.-T.
        • Coquillat G.
        • et al.
        Plasma dopamine β-hydroxylase in a noradrenalin-secreting pheochromocytoma.
        Clin. Chim. Acta. 1976; 70: 455-458
        • Bax N.D.S.
        • Boulton A.J.M.
        • Woods H.F.
        • et al.
        Clinical and biochemical effects of parachlorophenylalanine in a patient with the carcinoid syndrome.
        Postgrad. Med. J. 1982; 58: 493-495
        • Beaton H.L.
        Carcinoid tumors of the alimentary tract.
        CA. 1982; 32: 92-99
        • Beaton H.
        • Homan W.
        • Dineen P.
        Gastrointestinal carcinoids and the malignant carcinoid syndrome.
        Surg. Gynecol. Obstet. 1981; 152: 268-272
        • Cariei F.
        • Polak J.M.
        Antibodies to neuron-specific enolase for the delineation of the entire diffuse neuroendocrine system in health and disease.
        Semin. Diag. Pathol. 1984; 1: 59-70
        • Costello C.
        Carcinoid tumor metastases: Prospective study of 22 patients.
        Am. J. Surg. 1975; 130: 756-759
        • Dabek J.T.
        Bronchial carcinoid tumour with acromegaly in two patients.
        J. Clin. Endocrinol. Metab. 1974; 38: 329
        • Davis R.B.
        The concentration of serotonin in normal human serum as determined by an improved method.
        J. Lab. Clin. Med. 1959; 54: 344-351
        • Engelman K.
        • Lovenberg W.
        • Sjoerdsma A.
        Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome.
        N. Engl. J. Med. 1967; 277: 1103-1108
        • Feldman J.M.
        • Plonk J.W.
        • Bivens C.E.
        Alterations of pituitary-gonadal function in the carcinoid syndrome.
        Am. J. Med. Sei. 1974; 268: 215-226
        • Feldman J.M.
        • Plonk J.W.
        • Admiraal J.
        • et al.
        Plasma amino acids in patients with the carcinoid syndrome.
        Cancer. 1976; 38: 2127-2131
        • Feldman J.M.
        • Plonk J.W.
        • Bivens C.H.
        Inhibitory effect of serotonin antagonists on growth hormone release in acromegalic patients.
        Clin. Endocrinol. 1976; 5: 70-78
        • Feldman J.M.
        • Plonk J.W.
        Gastrointestinal and metabolic function in patients with the carcinoid syndrome.
        Am. J. Med. Sei. 1977; 273: 43-54
        • Feldman J.M.
        • Plonk J.W.
        Pituitary-gonadal function in the carcinoid syndrome: Effect of parachlorophenylalanine therapy.
        Horm. Metab. Res. 1977; 9: 156-160
        • Feldman J.M.
        • Jones R.S.
        Carcinoid syndrome from gastrointestinal carcinoid without liver metastasis.
        Ann. Surg. 1982; 196: 33-37
        • Friesen S.R.
        Tumors of the endocrine pancreas.
        N. Engl. J. Med. 1982; 306: 580-590
        • Gerbitz K.-D.
        • Summer J.
        • Thallemer J.
        Brain-specific proteins: Solid-phase immunobioluminescence assay for neuron-specific enolase in human plasma.
        Clin. Chem. 1984; 30: 382-386
        • Godwin III, J.D.
        Carcinoid tumors: An analysis of 2837 cases.
        Cancer. 1975; 36: 560-569
        • Gomez-Pan A.
        • Scanlon M.F.
        • Thorner M.O.
        • et al.
        Effect of somatostatin on abnormal growth hormone and prolactin secretion in patients with the carcinoid syndrome.
        Clin. Endocrinol. 1979; 10: 575-581
        • Grahame-Smith D.G.
        The carcinoid syndrome.
        Am. J. Cardiol. 1968; 21: 376-387
        • Grahame-Smith D.G.
        The carcinoid syndrome.
        William Heinemann, London1972
        • Grahame-Smith D.G.
        The carcinoid syndrome.
        in: Bondy P.K. Rosenberg L.E. Metabolic Control and Disease. Edition 8. W. B. Saunders, Philadelphia1980
        • Hallwright G.P.
        • North K.A.K.
        • Reid J.D.
        Pigmentation and Cushing’s syndrome due to malignant tumor of the pancreas.
        J. Clin. Endocrinol. 1964; 24: 496-500
        • Harris A.L.
        Chemotherapy for the carcinoid syndrome.
        Cancer Chemother. Pharmacol. 1981; 5: 133-138
        • Hattori M.
        • Fukase M.
        • Yoshimi H.
        • et al.
        Ectopic production of human chorionic gonadotropin in malignant tumors.
        Cancer. 1978; 42: 2328-2333
        • Jarett L.
        • Lacy P.E.
        • Kipnis D.M.
        Characterization by immunofluorescence of an ACTH-like substance in nonpituitary tumors from patients with hyperadrenocorticism.
        J. Clin. Endocrinol. 1964; 24: 543-549
        • Jepson J.B.
        Paper chromatography of urinary indoles.
        Lancet. 1955; 2: 1009
        • Kabakow B.
        • Weinstein J.B.
        • Ross G.
        Effect of iproniazid upon serotonin metabolism.
        Fed. Proc. 1958; 17: 382
        • Kaplan E.L.
        • Sizemore G.W.
        • Peskin G.W.
        • et al.
        Humoral similarities of carcinoid tumors and medullary carcinomas of the thyroid.
        Surgery. 1973; 74: 21-29
        • Kowlessar O.D.
        • Williams R.C.
        • Law D.H.
        • et al.
        Urinary excretion of 5-hydroxyindoleacetic acid in diarrheal states with special reference to nontropical sprue.
        N. Engl. J. Med. 1958; 259: 340-341
        • Lancranjan I.
        • Wirz-Justice A.
        • Puhringer W.
        • et al.
        Effect of 1–5 hydroxytryptophan infusion on growth hormone and prolactin secretion in man.
        J. Clin. Endocrinol. Metab. 1977; 45: 588
        • Lembeck F.
        5-Hydroxytryptamine in a carcinoid tumour.
        Nature. 1953; 172: 910-911
        • Levine R.J.
        • Sjoerdsma A.
        Pressor amines and the carcinoid flush.
        Ann. Intern. Med. 1963; 58: 818-828
        • Long R.G.
        • Peters J.R.
        • Bloom S.R.
        • et al.
        Somatostatin, gastrointestinal peptides, and the carcinoid syndrome.
        Gut. 1981; 22: 549-553
        • MacDonald R.A.
        A Study of 356 carcinoids of the gastrointestinal tract.
        Am. J. Med. 1956; 21: 867-878
        • Marks C.
        Carcinoid Tumors, A Clinicopathologic Study.
        G. K. Hall, Boston1979
        • Mattingly T.W.
        • Sjoerdsma A.
        The cardiovascular manifestations of functioning carcinoid tumors.
        Mod. Concepts Cardiovasc. Dis. 1956; 25: 337-341
        • Melmon K.L.
        • Lovenberg W.
        • Sjoerdsma A.
        Characteristics of carcinoid tumor kallikrein: Identification of lysyl-bradykinin as a peptide it produces in vitro.
        Clin. Chim. Acta. 1965; 12: 292-297
        • Melmon K.L.
        • Sjoerdsma A.
        • Oates J.A.
        • et al.
        Treatment of malabsorption and diarrhea of the carcinoid syndrome with methysergide.
        Gastroenterology. 1965; 48: 18-24
        • Misiewicz J.J.
        • Waller S.L.
        • Eisner M.
        Motor responses of human gastrointestinal tract to 5-Hydroxytryptamine in vivo and in vitro.
        Gut. 1966; 7: 208-216
        • Moertel C.G.
        • Beahrs O.H.
        • Woolner L.B.
        • et al.
        “Malignant carcinoid syndrome” associated with noncarcinoid tumors.
        N. Engl. J. Med. 1965; 273: 244-248
        • Nash D.T.
        • Brin M.
        Malabsorption in malignant carcinoid with normal 5-HIAA.
        N.Y. State J. Med. 1964; 64: 1128-1131
        • Oates J.A.
        • Sjoerdsma A.
        A unique syndrome associated with secretion of 5-hydroxytryptophan by metastatic gastric carcinoids.
        Am. J. Med. 1962; 32: 333-342
        • Oates J.A.
        • Melmon K.
        • Sjoerdsma A.
        • et al.
        Release of kinin peptide in the carcinoid syndrome.
        Lancet. 1964; 1: 514-517
        • Oates J.A.
        • Pettinger W.A.
        • Doctor R.B.
        Evidence for the release of bradykinin in carcinoid syndrome.
        J. Clin. Invest. 1966; 45: 173-180
        • Oates J.A.
        • Butler T.C.
        Pharmacologic and endocrine aspects of carcinoid syndrome.
        Adv. Pharmacol. 1967; 5: 109-127
        • Oberg K.
        • Wide L.
        hCG and hCG subunits as tumour markers in patients with endocrine pancreatic tumours and carcinoids.
        Acta Endocrinol. 1981; 98: 256-260
        • Oberg K.
        • Guna K.
        • Alm G.
        Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome.
        N. Engl. J. Med. 1983; 309: 129-133
        • Page I.H.
        • Corcoran A.C.
        • Udenfriend S.
        • et al.
        Argentaffinoma as endocrine tumour.
        Lancet. 1955; 1: 198-199
        • Pearse A.G.E.
        The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept.
        J. Histochein. Cytochem. 1969; 17: 303-313
        • Pearse A.G.E.
        Neurocristopathy, neuroendocrine pathology and the APUD concept.
        Z. Krebsforsch. 1975; 84: 1-18
        • Pearse A.G.E.
        • Takor T.T.
        Neuroendocrine embryology and the APUD concept.
        Clin. Endocrinol. 1976; 5: 229s-244s
        • Peart W.S.
        • Robertson J.I.S.
        The effect of a serotonin antagonist (UML 491) in carcinoid disease.
        Lancet. 1961; 2: 1172-1174
        • Pernow B.
        • Waldenstrom J.
        Determination of 5-hydroxytryptamine, 5-hydroxyin-doleacetic acid and histamine in thirty-three cases of carcinoid tumors (argentaffinoma).
        Am. J. Med. 1957; 23: 16-25
        • Plonk J.W.
        • Feldman J.M.
        Carcinoid arthropathy.
        Arch. Intern. Med. 1974; 134: 651-654
        • Rich L.L.
        • Lisa C.P.
        • Nasser W.K.
        Carcinoid pericarditis.
        Am. J. Med. 1973; 54: 522-527
        • Robertson J.I.S.
        • Peart W.S.
        • Andrews T.M.
        The mechanism of facial flushes in the carcinoid syndrome.
        Quart. J. Med. 1962; 121: 103-123
        • Scheithauer B.W.
        • Carpenter P.C.
        • Bloch B.
        • et al.
        Ectopic secretion of a growth hormone-releasing factor.
        Am. J. Med. 1984; 76: 605-616
        • Shames J.M.
        • Dhurandhar N.R.
        • Blackard W.G.
        Insulin-secreting bronchial carcinoid tumor with widespread metastases.
        Am. J. Med. 1968; 44: 632-637
        • Sjoerdsma A.
        • Weissbach H.
        • Terry L.L.
        • et al.
        Further observations on patients with malignant carcinoid.
        Am. J. Med. 1957; 23: 5-15
        • Skrabanek P.
        • Nat R.
        • Powell D.
        Unifying concept of non-pituitary ACTH-secreting tumors: Evidence of common origin of neural-crest tumors, carcinoids, and oat-cell carcinomas.
        Cancer. 1978; 42: 1263-1269
        • Thorson A.H.
        Studies on carcinoid disease.
        Acta Med. Scand. [Suppl.]. 1958; 334: 1-132
        • Tischler A.S.
        • Dighter M.A.
        • Biales B.
        • et al.
        Neuroendocrine neoplasms and their cells of origin.
        N. Engl. J. Med. 1977; 296: 919-925
        • Tyce G.M.
        • Greagan E.T.
        Measurement of free and bound 5-hydroxytryptophan in plasma by liquid chromatography with electrochemical detection.
        Anal. Biochem. 1981; 112: 143-150
        • Udenfriend S.
        • Titus E.
        • Weissbach H.
        The identification of 5-hydroxy-3-indole-acetic acid in normal urine and a method for its assay.
        J. Biol. Chem. 1955; 216: 499-505
        • van der Sluys Veer J.
        • Choufoer J.C.
        • Querido A.
        • et al.
        Metastasising islet-cell tumour of the pancreas associated with hypoglycaemia and carcinoid syndrome.
        Lancet. 1964; 1: 1416-1419
        • Waldenstrom J.
        • Ljungberg E.
        Studies on the functional circulatory influence from metastasizing carcinoid (argentaffine, enterochromaffine) tumors and their possible relation to enteramine production.
        Acta Med. Scand. 1955; 153: 293-331
        • Wilkin J.K.
        Flushing Reactions: Consequences and mechanisms.
        Ann. Intern. Med. 1981; 95: 468-476
        • Wilkin J.K.
        • Rountree C.B.
        Blockade of carcinoid flush with cimetidine and clonidine.
        Arch. Dermatol. 1982; 118: 109-111
        • Williams E.D.
        • Sandler M.
        The classification of carcinoid tumours.
        Lancet. 1963; 1: 238-239

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0272-2712(18)30903-X

      Copyright

      © 1984 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX